MedTrace Logo

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

NCT04341389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 508

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.

Conditions

Interventions

BIOLOGICAL

Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)

Intramuscular injection

OTHER

Placebo

Intramuscular injection

Sponsors & Collaborators

  • CanSino Biologics Inc.

    collaborator INDUSTRY

  • Jiangsu Province Centers for Disease Control and Prevention

    collaborator NETWORK

  • Hubei Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Zhongnan Hospital

    collaborator OTHER

  • Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

    lead OTHER

Principal Investigators

  • Fengcai Zhu, MD · Jiangsu Province Centers of Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-12
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341389 on ClinicalTrials.gov